Scholarlink

Purpose <p>This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.</p> Patients and methods <p>This retrospective cohort study was conducted at two tertiary medical centers in Taiwan between January 1, 2018, and June 30, 2024. Patients with severe asthma who received continuous treatment with either mepolizumab or benralizumab for a minimum of 12 months were included. Pulmonary function parameters, asthma exacerbation rates, Asthma Control Test (ACT) scores, peripheral blood eosinophil counts, and asthma remission status were assessed at baseline and after 12 months of treatment.</p> Results <p>A total of 60 patients were included, with 34 receiving mepolizumab and 26 receiving benralizumab for the treatment of severe asthma. After 12 months, the benralizumab group showed a significant improvement in pulmonary function, with mean FEV₁% increasing from 61.6% to 69.5% (∆FEV₁%: +7.9; <i>p =</i> 0.001). Both groups exhibited significant reductions in blood eosinophil counts: −487.1/μL in the mepolizumab group (<i>p &lt;</i> 0.001) and −520.3/μL in the benralizumab group (<i>p &lt;</i> 0.001). The criteria constituting clinical remission at 12 months were met in 44.1% of patients in the mepolizumab group and 30.8% in the benralizumab group, with no statistically significant difference between the groups. Both treatments were similarly effective in reducing exacerbation frequency and enabling attainment of clinical remission criteria at 12 months, tapering off oral corticosteroids, and improving symptom control.</p> Conclusions <p>After 12 months of treatment, mepolizumab and benralizumab demonstrated comparable efficacy in asthma control, exacerbation reduction, and clinical remission in patients with severe eosinophilic asthma. However, benralizumab showed a tendency toward greater improvement in lung function.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Wei-Chun Huang,
  • Yi-Luen Shen,
  • Wen-Chien Cheng,
  • Chien-Wen Huang,
  • Chia-Hung Chen,
  • Chih- Yen Tu,
  • Wu-Huei Hsu

摘要

Purpose

This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.

Patients and methods

This retrospective cohort study was conducted at two tertiary medical centers in Taiwan between January 1, 2018, and June 30, 2024. Patients with severe asthma who received continuous treatment with either mepolizumab or benralizumab for a minimum of 12 months were included. Pulmonary function parameters, asthma exacerbation rates, Asthma Control Test (ACT) scores, peripheral blood eosinophil counts, and asthma remission status were assessed at baseline and after 12 months of treatment.

Results

A total of 60 patients were included, with 34 receiving mepolizumab and 26 receiving benralizumab for the treatment of severe asthma. After 12 months, the benralizumab group showed a significant improvement in pulmonary function, with mean FEV₁% increasing from 61.6% to 69.5% (∆FEV₁%: +7.9; p = 0.001). Both groups exhibited significant reductions in blood eosinophil counts: −487.1/μL in the mepolizumab group (p < 0.001) and −520.3/μL in the benralizumab group (p < 0.001). The criteria constituting clinical remission at 12 months were met in 44.1% of patients in the mepolizumab group and 30.8% in the benralizumab group, with no statistically significant difference between the groups. Both treatments were similarly effective in reducing exacerbation frequency and enabling attainment of clinical remission criteria at 12 months, tapering off oral corticosteroids, and improving symptom control.

Conclusions

After 12 months of treatment, mepolizumab and benralizumab demonstrated comparable efficacy in asthma control, exacerbation reduction, and clinical remission in patients with severe eosinophilic asthma. However, benralizumab showed a tendency toward greater improvement in lung function.